Investigational drug · Phase 3
CAPEOX
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Neoplasms, Colon, Colonic Neoplasms, Colorectal Adenoma.
Phase 3Last checked: Nov 19, 2026Latest source record: May 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
132
Any phase or sponsor naming "CAPEOX"
First trial start
2023
Aug 1, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CAPEOX", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neoplasms, Colon
- Colonic Neoplasms
- Colorectal Adenoma
- Colon Cancer
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "CAPEOX" as an intervention, largest first.
- Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon CancerPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT03125980 · 1,370 participants (planned) · Start May 2017 · Primary completion May 2022
Drug: capecitabine plus oxaliplatin before and after surgery; capecitabine plus oxaliplatin after surgery · For: Locally Advanced Colon Cancer
Sites: Shanghai, China
- Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1)Pivotal-lookingStatus unknown
Peking University Cancer Hospital & InstituteAcademic, hospital or other
NCT03199989 · 1,254 participants (planned) · Start Jun 1, 2017 · Primary completion Jul 31, 2021
Drug: CapeOX(Capecitabine+Oxaliplatin) · For: Adjuvant Chemotherapy
Sites: Beijing, China
- Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon CancerPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT05855200 · 892 participants (planned) · Start Aug 1, 2023 · Primary completion Mar 19, 2029
Drug: Dostarlimab; CAPEOX and 1 more · For: Colonic Neoplasms; Neoplasms, Colon
Sites: Tucson, Arizona; Los Angeles, California; New Haven, Connecticut · 266 sites in all
- Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon CancersPivotal-lookingRecruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT05194878 · 840 participants (planned) · Start Dec 1, 2021 · Primary completion Dec 2024
Drug: neoadjuvant chemotherapyI; adjuvant chemotherapy · For: Colon Cancer Stage II; Colon Cancer Stage III
Sites: Guangzhou, China
- Study of Adjuvant ONO-4538 With Resected Gastric CancerPivotal-lookingCompleted
Ono Pharmaceutical Co., Ltd.Industry
NCT03006705 · 800 participants · Start Jan 31, 2017 · Primary completion Aug 17, 2022
Drug: Nivolumab; Tegafur-gimeracil-oteracil potassium and 3 more · For: Gastric Cancer
Sites: Anhui Province, China; Beijing, China; Cuangdong Province, China · 108 sites in all
Hansoh BioMedical R&D CompanyIndustry
NCT06621563 · 780 participants (planned) · Start Dec 14, 2024 · Primary completion Mar 30, 2026
Drug: HS-20117 combined HS-20093; HS-20117 combined Platinum-containing chemotherapy and 4 more · For: Solid Tumors; Non-Small Cell Lung Cancer; Colorectal Cancer
Sites: Tianjin, China
- A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal CancerPivotal-lookingActive, not recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04854668 · 748 participants · Start May 27, 2021 · Primary completion Dec 31, 2024
Drug: Anlotinib hydrochloride capsule; Bevacizumab and 2 more · For: Metastatic Colorectal Cancer
Sites: Chizhou, China; Fuzhou, China; Hefei, China · 92 sites in all
- Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal CarcinomatosisPivotal-lookingStatus unknown
Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityAcademic, hospital or other
NCT04370925 · 688 participants (planned) · Start Jun 4, 2020 · Primary completion Apr 30, 2024
Drug: Systemic chemotherapy · For: Colorectal Cancer
Sites: Beijing, China; Chongqing, China; Foshan, China · 37 sites in all
- Study of ONO-4538 in Gastric CancerPivotal-lookingCompleted
Ono Pharmaceutical Co., Ltd.Industry
NCT02746796 · 680 participants (planned) · Start Mar 2016 · Primary completion Jan 2020
Drug: ONO-4538; Oxaliplatin and 3 more · For: Gastric Cancer
Sites: Nagoya, Japan; Hirosaki, Japan; Misawa, Japan · 130 sites in all
- The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric CancerStatus unknown
Fujian Medical UniversityAcademic, hospital or other
NCT06235164 · 585 participants · Start Jan 1, 2019 · Primary completion Dec 30, 2022
Drug: immune checkpoint inhibitors: sintilimab, nivolumab, and camrelizumab · For: Locally Advanced Gastric Cancer
Sites: Fuzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Exploratory Study on the Association Between Pre-treatment Factors and Hematological Toxicity in Colorectal Cancer Patients Receiving CapeOX (Capecitabine Plus Oxaliplatin) Therapy.
Kishimoto M, Tokunaga J · Cureus 2026
- Longitudinal plasma phosphorylated neurofilament-heavy chain levels in oxaliplatin-induced peripheral neuropathy: a prospective multi-institutional exploratory study.
Motoo Y, Shinozaki K, Miura M, et al. · Cancer Chemother Pharmacol 2026
- A case of severe enteritis following CapeOX therapy in a postoperative rectal cancer patient with m.3243A>G-associated mitochondrial disease.
Kawakubo H, Ryu S, Imaizumi Y, et al. · Int Cancer Conf J 2026
- Evolution of Real-World Treatment Patterns over Time in Patients with HER2-Negative Advanced Gastric Cancer: A Retrospective Database Cohort Study from Japan.
Hironaka S, Kimijima Y, Shinno Y, et al. · Adv Ther 2026
- Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Therapy Selection for High-Risk Stage II Colon Cancer.
Cotan HT, Orlov-Slavu CM, Lazar A, et al. · Chirurgia (Bucur) 2026
- First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial.
Liu Y, Zhang Y, Lin R, et al. · Signal Transduct Target Ther 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.